Payment overview · 2025
General Payments
$183.33
3 reported records · 2 companies
Healthcare provider profile · identity verified
Callie Ann Smith, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HIGH SPRINGS, FL · NPI 1710356282
Verified facts
What the public records show
CMS Open Payments records show Callie Ann Smith, ARNP received $183.33 in general payments during 2025 across 3 reported records.
Recor Medical Inc accounted for 81.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Recor Medical Inc | Unresolved — no canonical attribution shown | $149.29 | 81.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.04 | 18.6% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $183.33 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $149.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.04 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.04 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 356 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 347 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 290 | 101 |
| Omeprazole | Omeprazole | 262 | 94 |
| Pravastatin Sodium | Pravastatin Sodium | 261 | 86 |
| Losartan Potassium | Losartan Potassium | 198 | 60 |
| Lisinopril | Lisinopril | 189 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 50 |
| Gabapentin | Gabapentin | 143 | 54 |
| Metformin Hcl | Metformin Hcl | 136 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 41 |
| Montelukast Sodium | Montelukast Sodium | 120 | 40 |
| Meloxicam | Meloxicam | 109 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 37 |
| Eliquis | Apixaban | 99 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 97 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 31 |
| Azithromycin | Azithromycin | 95 | 77 |
| Glimepiride | Glimepiride | 89 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 36 |
| Methylprednisolone | Methylprednisolone | 72 | 67 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 20 |
| Potassium Chloride | Potassium Chloride | 67 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 22 |
| Trazodone Hcl | Trazodone Hcl | 63 | 20 |
| Ezetimibe | Ezetimibe | 62 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 26 |
| Fluconazole | Fluconazole | 60 | 33 |
| Furosemide | Furosemide | 60 | 26 |
| Allopurinol | Allopurinol | 58 | 20 |
| Cephalexin | Cephalexin | 55 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 17 |
| Metformin Hcl Er | Metformin Hcl | 49 | 15 |
| Ozempic | Semaglutide | 46 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 29 |
| Simvastatin | Simvastatin | 43 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 11 |
| Spironolactone | Spironolactone | 38 | 12 |
| Carvedilol | Carvedilol | 37 | 15 |
| Celecoxib | Celecoxib | 36 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Atenolol | Atenolol | 34 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 13 |
| Meclizine Hcl | Meclizine Hcl | 32 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | 12 |
| Famotidine | Famotidine | 29 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Prednisone | Prednisone | 24 | 18 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 12 |
| Bumetanide | Bumetanide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $183.33 · 3 records | Recor Medical Inc | MOUNJARO, Paradise Ultrasound Renal Denervation System, ZEPBOUND | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error